Last $0.71 USD
Change Today +0.0002 / 0.03%
Volume 319.1K
RNN On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (RNN) Snapshot

Open
$0.70
Previous Close
$0.71
Day High
$0.71
Day Low
$0.70
52 Week High
01/13/14 - $1.85
52 Week Low
11/7/13 - $0.37
Market Cap
126.6M
Average Volume 10 Days
847.1K
EPS TTM
$-0.13
Shares Outstanding
178.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REXAHN PHARMACEUTICALS INC (RNN)

Related News

No related news articles were found.

rexahn pharmaceuticals inc (RNN) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (RNN) Details

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.

16 Employees
Last Reported Date: 03/21/14

rexahn pharmaceuticals inc (RNN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $380.8K
President and Chief Operating Officer
Total Annual Compensation: $268.8K
Founder, Chairman of the Board and Chief Scie...
Total Annual Compensation: $319.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.1K
Compensation as of Fiscal Year 2013.

rexahn pharmaceuticals inc (RNN) Key Developments

Rexahn Pharmaceuticals, Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for Rx-3117 in Treatment of Pancreatic Cancer

Rexahn Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its drug RX-3117 for the treatment of patients with pancreatic cancer. RX-3117 is a next generation, cancer-specific nucleoside analog. Rexahn is currently enrolling patients in a Phase Ib clinical trial in cancer patients and expects to complete this trial in the first quarter of 2015. The FDA's office of Orphan Drug Products grants orphan status to support development of medicines for rare disorders, defined as diseases that affect fewer than 200,000 people in the United States. Orphan drug designation provides Rexahn with certain benefits, including limited market exclusivity upon regulatory approval if received, exemption of FDA application fees and tax credits for qualified clinical trials. Preclinical studies have shown that RX-3117 maintains its anti-tumor activity in human cancer cell lines that are resistant to gemcitabine, a chemotherapy drug used to treat pancreatic cancer. Gemcitabine resistance represents a major problem in the treatment of cancer patients. In pancreatic cancer patients who have been treated with gemcitabine, up to 40% of patients became resistant to gemcitabine after 30 days. RX-3117 has shown to be effective in treating cancer cells that have become gemcitabine resistant. If the results of Phase Ib trial and future trials show similar results in gemcitabine resistant patients, this would represent a major breakthrough in the treatment of pancreatic cancer patients.

Rexahn Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 03:00 PM

Rexahn Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 03:00 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Vikas Sharma, Director of Business Development.

Rexahn Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Rexahn Pharmaceuticals, Inc. reported financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations for the second quarter ended June 30, 2014 was $3.51 million, compared to a loss from operations of $1.91 million for the same quarter ended June 30, 2013. Net loss for the six months ended June 30, 2014 was $14.41 million, or $0.08 loss per share, compared to a net loss of $4.64 million, or $0.04 loss per share, for the same period ended June 30, 2013. Loss from operations for the six months ended June 30, 2014 was $6.27 million, compared to a loss from operations of $3.82 million for the same period ended June 30, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNN:US $0.71 USD +0.0002

RNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RNN.
View Industry Companies
 

Industry Analysis

RNN

Industry Average

Valuation RNN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit www.rexahn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.